Please cite this article in press Pavankumar P. Wankhade et al., Alzheimer’s Disease: A Comprehensive Review Of Pathology, Epidemiology, And Therapeutic Advances., Indo Am. J. P. Sci, 2024; 11 (08).

1.De-Paula V.J., Radanovic M., Diniz B.S., Forlenza O.V. Alzheimer’s disease. Sub-Cell. Biochem. 2012;65:329–352. doi: 10.1007/978-94-007-5416-4_14.
2.Cipriani G., Dolciotti C., Picchi L., Bonuccelli U. Alzheimer and his disease: A brief history. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2011;32:275–279. doi: 10.1007/s10072-010-0454-7.
3.Blass J.P. Alzheimer’s disease. Dis. A Mon. Dm. 1985;31:1–69. doi: 10.1016/0011-5029(85)90025-2.
4.Terry R.D., Davies P. Dementia of the Alzheimer type. Annu. Rev. Neurosci. 1980;3:77–95. doi: 10.1146/annurev.ne.03.030180.000453.
5.Rathmann K.L., Conner C.S. Alzheimer’s disease: Clinical features, pathogenesis, and treatment.Drug Intell. Clin. Pharm. 1984;18:684–691. doi: 10.1177/106002808401800902.
6.Yiannopoulou K.G., Papageorgiou S.G. Current and future treatments in alzheimer disease: An update. J. Cent. Nerv. Syst. Dis. 2020:12. doi: 10.1177/1179573520907397.
7.Livingston G., Huntley J., Sommerlad A., Ames D., Ballard C., Banerjee S., Brayne C., Burns A., Cohen-Mansfield J., Cooper C., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413–446. doi: 10.1016/S0140-6736(20)30367-6.
8.Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Zentralbl. Nervenh. Psych. 1907;18:177-9.
9.Yang HD, Kim DH, Lee SB, Young LD. History of Alzheimer’s Disease. Dementia and Neurocognitive Disorders. 2016 Dec 1;15(4):115-21.
10.Soria Lopez JA, Gonzalez HM, and Leger GC. Chapter 13 – Alzheimer’s disease. Handbook of Clinical Neurology 2019; 167: 231-255.
11.Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications. 1984 May 16;120(3):885-90.
12.Brion JP, Couck AM, Passareiro E, Flament-Durand J. Neurofibrillary tangles of Alzheimer’s disease: an immunohistochemical study. Journal of Submicroscopic Cytology. 1985 Jan 1;17(1):89-96.
13.McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984 Jul 1;34(7):939-44.
14.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011 May;7(3):263-9.
15.Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018 Apr;14(4):535-62.
16.Breijyeh, Z, and Karaman, R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. (2020) 25:3–9. doi: 10.3390/molecules25245789
17.Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement. (2022) 18:700–89. doi: 10.1002/alz.12638
18.Barnes, LL. Alzheimer disease in African American individuals: increased incidence or not enough data? Nat Rev Neurol. (2022) 18:56–62. doi: 10.1038/s41582-021-00589-3
19.Churchwell, K, Elkind, MSV, Benjamin, RM, Carson, AP, Chang, EK, Lawrence, W, et al. Call to action: structural racism as a fundamental driver of health disparities: a presidential advisory from the American Heart Association. Circulation. (2020) 142:e454–68. doi: 10.1161/CIR.0000000000000936
20.Dreeben, O. Health status of African Americans. J Health Soc Policy. (2001) 14:1–17. doi: 10.1300/J045v14n01_01
21.Li, X, Feng, X, Sun, X, Hou, N, Han, F, and Liu, Y. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2019. Front Aging Neurosci. (2022) 14:937486. doi: 10.3389/fnagi.2022.937486
22.Liu, RM. Aging, cellular senescence, and Alzheimer’s disease. Int J Mol Sci. (2022) 23:1989. doi: 10.3390/ijms23041989
23.Dickson, DW, Crystal, HA, Mattiace, LA, Masur, DM, Blau, AD, Davies, P, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. (1992) 13:179–89. doi: 10.1016/0197-4580(92)90027-u
24.Golde, TE. Alzheimer’s disease—the journey of a healthy brain into organ failure. Mol Neurodegener. (2022) 17:2. doi: 10.1186/s13024-022-00523-1
25.De Strooper, B. Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. (2007) 8:141–6. doi: 10.1038/sj.embor.7400897
26.Farrer, LA, Cupples, LA, Haines, JL, Hyman, B, Kukull, WA, Mayeux, R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease Meta analysis consortium. JAMA. (1997) 278:1349–56. doi: 10.1001/jama.1997.03550160069041
27.Seaks, CE, and Wilcock, DM. Infectious hypothesis of Alzheimer disease. PLoS Pathog. (2020) 16:e1008596. doi: 10.1371/journal.ppat.1008596
28.Yeo, RA, Arden, R, and Jung, RE. Alzheimer’s disease and intelligence. Curr Alzheimer Res. (2011) 8:345–53. doi: 10.2174/156720511795745276
29.Futch, HS, Croft, CL, Truong, VQ, Krause, EG, and Golde, TE. Targeting psychologic stress signaling pathways in Alzheimer’s disease. Mol Neurodegener. (2017) 12. doi: 10.1186/s13024-017-0190-z
30.Alzheimer’s Association. (2020). 2020 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 16(3), 391-460.
31.World Health Organization. (2020). Dementia: Key Facts. Retrieved from https://www.who.int/news-room/fact-sheets/detail/dementia
32.Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., … & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413-446.
33.(2015) Alzheimer’s disease genetics fact sheet. National Institute of Aging.
34.Rygiel K (2016) Novel strategies for alzheimer’s disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol 48: 629-636.
35.Hardy J, De Strooper B (2017) Alzheimer’s disease: Where next for anti-amyloid therapies? Brain 140: 853-855.
36.Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189.
37.Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron. 2014;82:756–771. doi: 10.1016/j.neuron.2014.05.004.
38.Singh S.K., Srivastav S., Yadav A.K., Srikrishna S., Perry G. Overview of Alzheimer’s disease and some therapeutic approaches targeting abeta by using several synthetic and herbal compounds. Oxidative Med. Cell. Longev. 2016;2016:7361613. doi: 10.1155/2016/7361613.
39.Cras P., Kawai M., Lowery D., Gonzalez-DeWhitt P., Greenberg B., Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 1991;88:7552–7556. doi: 10.1073/pnas.88.17.7552.
40.Perl D.P. Neuropathology of Alzheimer’s disease. Mt. Sinai J. Med. N. Y. 2010;77:32–42. doi: 10.1002/msj.20157.
41.Armstrong R.A. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol. 2009;47:289–299.
42.Chen G.F., Xu T.H., Yan Y., Zhou Y.R., Jiang Y., Melcher K., Xu H.E. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 2017;38:1205–1235. doi: 10.1038/aps.2017.28.
43.Tabaton M., Piccini A. Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer’s disease. Int. J. Exp. Pathol. 2005;86:139–145. doi: 10.1111/j.0959-9673.2005.00428.x.
44.Brion J.P. Neurofibrillary tangles and Alzheimer’s disease. Eur. Neurol. 1998;40:130–140. doi: 10.1159/000007969.
45.Metaxas A., Kempf S.J. Neurofibrillary tangles in Alzheimer’s disease: Elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen. Res. 2016;11:1579–1581. doi: 10.4103/1673-5374.193234.
46.Overk C.R., Masliah E. Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem Pharm. 2014;88:508–516. doi: 10.1016/j.bcp.2014.01.015.
47.Lleo A., Nunez-Llaves R., Alcolea D., Chiva C., Balateu-Panos D., Colom-Cadena M., Gomez-Giro G., Munoz L., Querol-Vilaseca M., Pegueroles J., et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid. Mol. Cell. Proteom. Mcp. 2019;18:546–560. doi: 10.1074/mcp.RA118.001290.
48.Tarawneh R., D’Angelo G., Crimmins D., Herries E., Griest T., Fagan A.M., Zipfel G.J., Ladenson J.H., Morris J.C., Holtzman D.M. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer Disease. JAMA Neurol. 2016;73:561–571. doi: 10.1001/jamaneurol.2016.0086.
49.Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 297(5580), 353-356.
50.Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989). Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron, 3(4), 519-526.
51.Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., … & Kummer, M. P. (2015). Neuroinflammation in Alzheimer’s disease. The Lancet Neurology, 14(4), 388-405.
52.Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nature Reviews Neuroscience, 20(3), 148-160.
53.Spires-Jones, T. L., & Hyman, B. T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron, 82(4), 756-771.
54.Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience, 12(12), 723-738.
55.Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011). Alzheimer’s disease: the challenge of the second century. Science translational medicine, 3(77), 77sr1-77sr1.
56.Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015). Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimer’s & Dementia, 11(1), 58-69.
57.McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack Jr, C. R., Kawas, C. H., … & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 263-269.
58.Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., … & Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280-292.
59.Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. (2002). Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. The American Journal of Psychiatry, 159(5), 708-714.
60.Ballard, C., O’Brien, J., James, I., Mynt, P., Lana, M. M., Potkins, D., … & Wilcock, G. (2009). Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. International Psychogeriatrics, 21(2), 361-376.
61.Volicer, L., Harper, D. G., Manning, B. C., Goldstein, R., & Satlin, A. (2001). Sundowning and circadian rhythms in Alzheimer’s disease. The American Journal of Psychiatry, 158(5), 704-711.
62.American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
63.Jack, C. R. Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., … & NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease. Alzheimer’s & Dementia, 14(4), 535-562.
64.Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., … & Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280-292.
65.Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
66.McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.
67.Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734.
68.Cummings J, Lee G, Mortsdorf T, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6(1):e12050.
69.Rolland Y, Pillard F, Klapouszczak A, et al. Exercise program for nursing home residents with Alzheimer’s disease: a 1-year randomized, controlled trial. J. Am. Geriatr. Soc. 2007; 55:158–65.
70.Ströhle A, Schmidt DK, Schultz F, et al. Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. Am. J. Geriatr. Psychiatry 2015; 23:1234–49.
71.Hoffmann K, Sobol NA, Frederiksen KS, et al. Moderate-to-high intensity physical exercise in patients with Alzheimer’s disease: A randomized controlled trial. J. Alzheimers Dis. 2015; 50:443–53.
72.Chapman SB, Aslan S, Spence JS, et al. Shorter term aerobic exercise improves brain, cognition, and cardiovascular fitness in aging. Front Aging Neurosci. 2013; 5:75.
73.Sacco G, Caillaud C, Ben Sadoun G, et al. Exercise plus cognitive performance over and above exercise alone in subjects with mild cognitive impairment. J. Alzheimers Dis. 2016; 50:19–25.
74.Forbes D, Forbes SC, Blake CM, et al. Exercise programs for people with dementia. Cochrane Database Syst. Rev. 2015; CD006489. DOI: 10.1002/14651858.CD006489.pub4.
75.Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer’s disease: a systematic review. Int. Psychogeriatr. 2014; 26:9–18.
76.Alzheimer’s Association. (2021). Alzheimer’s Disease Facts and Figures.
77.Cummings, J., et al. (2021). Alzheimer’s disease drug development pipeline: 2021.
78.Brodaty, H., & Donkin, M. (2009). Family caregivers of people with dementia. Dialogues in Clinical Neuroscience, 11(2), 217–228.
79.Chin, A. L., Negash, S., & Hamilton, R. (2011). Diversity and disparity in dementia: The impact of ethnoracial differences in Alzheimer disease. Alzheimer Disease & Associated Disorders, 25(3), 187–195.
80.Livingston, G., et al. (2017). Dementia prevention, intervention, and care. The Lancet, 390(10113), 2673–2734.
81.Long, J. M., & Holtzman, D. M. (2019). Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 179(2), 312–339.
82.Ienca, M., et al. (2017). Intelligent Assistive Technology for Alzheimer’s Disease and Other Dementias: A Systematic Review. Journal of Alzheimer’s Disease, 56(4), 1301–1340.